These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1091 related articles for article (PubMed ID: 16996584)

  • 1. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Hopkins L; Faught W; Fung-Kee-Fung M
    Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
    Richardson DL; Seamon LG; Carlson MJ; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE
    Gynecol Oncol; 2008 Nov; 111(2):233-6. PubMed ID: 18768214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
    Lan CY; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
    Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
    Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
    Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
    Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.
    Dizon DS; Weitzen S; Rojan A; Schwartz J; Miller J; Disilvestro P; Gordinier ME; Moore R; Tejada-Berges T; Pires L; Legare R; Granai CO
    Gynecol Oncol; 2006 Feb; 100(2):417-21. PubMed ID: 16336992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment.
    Barakat RR; Almadrones L; Venkatraman ES; Aghajanian C; Brown C; Shapiro F; Curtin JP; Spriggs D
    Gynecol Oncol; 1998 Apr; 69(1):17-22. PubMed ID: 9570993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
    Markman M; Liu PY; Rothenberg ML; Monk BJ; Brady M; Alberts DS
    J Clin Oncol; 2006 Mar; 24(9):1454-8. PubMed ID: 16549840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.